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Drug discoverySurface plasmon resonance (SPR) spectroscopy is a rapidly developing technique for the study of ligand bind-
ing interactions with membrane proteins, which are the major molecular targets for validated drugs and for
current and foreseeable drug discovery. SPR is label-free and capable of measuring real-time quantitative
binding afﬁnities and kinetics for membrane proteins interacting with ligand molecules using relatively
small quantities of materials and has potential to be medium-throughput. The conventional SPR technique
requires one binding component to be immobilised on a sensor chip whilst the other binding component
in solution is ﬂowed over the sensor surface; a binding interaction is detected using an optical method that
measures small changes in refractive index at the sensor surface. This review ﬁrst describes the basic SPR ex-
periment and the challenges that have to be considered for performing SPR experiments that measure mem-
brane protein–ligand binding interactions, most importantly having the membrane protein in a lipid or
detergent environment that retains its native structure and activity. It then describes a wide-range of mem-
brane protein systems for which ligand binding interactions have been characterised using SPR, including the
major drug targets G protein-coupled receptors, and how challenges have been overcome for achieving this.
Finally it describes some recent advances in SPR-based technology and future potential of the technique to
screen ligand binding in the discovery of drugs. This article is part of a Special Issue entitled: Structural
and biophysical characterisation of membrane protein–ligand binding.
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Membrane proteins are coded by up to 30% of the open reading
frames in known genomes [1–3], they have important roles in many bi-
ological processes (e.g. transport of ions andmolecules, control of trans-
membrane potential, generation and transduction of energy, signal
recognition and transduction, catalysis of chemical reactions) and mu-
tations in membrane proteins have been linked with a number of
human diseases [4–10]. The molecular targets for around 50–60% of
current validated medicines are membrane proteins and they remain
the principal target for new drug discovery [11–17]. Owing to the difﬁ-
culties in applying the main biophysical techniques for high-resolution
protein structure determination: X-ray crystallography and NMR spec-
troscopy, the number of structures of membrane proteins is still rela-
tively few, contributing less than 1% of protein structures in the
Protein Data Bank (PDB) [18], thus limiting the amount of information
available for traditional structure-based drug design. At the time of
writing, there are high-resolution structures determined for only
seventeen unique G-protein-coupled receptors (GPCRs) [19], which
represent the largest class ofmembrane protein drug target. Othermem-
brane protein drug targets include cytokine receptors, tyrosine and histi-
dine kinase receptors, antibody receptors, ligand- and voltage-gated ion
channels and transport proteins. It is important to have a range of
chemical, biochemical and biophysical techniques available for charac-
terisation of ligand binding by membrane proteins and for screening
libraries of compounds as potential drug candidates. A developing tech-
nique in this respect is surface plasmon resonance (SPR) spectroscopy,
which is label-free and enables measurement of real-time quantiﬁcation
of ligand-binding afﬁnities and kinetics using relatively small amounts of
membrane protein in a native or native-like environment and has poten-
tial to bemedium-throughput. Following a description of the SPR exper-
iment, this reviewﬁrst considers the challenges associatedwith applying
SPR-based methods to characterise ligand binding by membrane pro-
teins and then demonstrates how some of these have been overcome
with examples of its application to a range of speciﬁc membrane protein
systems. In some cases, this involves combination with results from
other experimental techniques and with molecular modelling. Finally it
describes some recent developments in SPR-based technology and con-
siders its future potential for drug discovery with membrane protein
targets.
2. The surface plasmon resonance experiment
Surface plasmon resonance (SPR) uses an optical method to mea-
sure a change in refractive index of the medium in close vicinity of
a metal surface that can be used to monitor the binding of analyte
molecules to receptor molecules immobilised on the metal surface[20,21]. This exploits the phenomenon of surface plasmon generation
in thin metal ﬁlms and the total internal reﬂection of light at a
surface-solution interface to produce an electromagnetic ﬁlm or eva-
nescent wave that extends a short distance (up to 300 nm) into the
solution (see other reviews for a more detailed description of the
theory behind surface plasmon generation [22–27] and references
therein). SPR has predominantly been developed and performed
using BIAcore™ technology [20,28–36] with the ﬁrst commercial in-
strument in 1991; an illustration of the basic instrument set up is
shown in Fig. 1A. The surface is typically a thin ﬁlm of gold on a
glass support that forms the ﬂoor of a small-volume (less than
100 nl) ﬂow cell through which an aqueous solution is passed contin-
uously. In order to detect the binding of an analyte molecule to a re-
ceptor molecule, the receptor molecule is usually immobilised on
the sensor surface and the analyte molecule is injected in the aqueous
solution through the ﬂow cell. Polarised light from a laser source is di-
rected through a prism to the under surface of the gold ﬁlm where
surface plasmons are generated at a critical angle of the incident
light. This absorption of light is seen as a decrease in intensity of the
reﬂected light. The critical angle is dependent on the refractive
index of the medium within 300 nm of the gold surface and changes
whenmolecules bind to the surface, e.g. when analyte molecules bind
to immobilised receptor molecules (Fig. 1B). The real-time response
of the SPR experiment is usually presented in the form of a
sensorgram (Fig. 1C). If interaction between the immobilised receptor
molecules and the analyte molecules occurs, the refractive index at
the surface of the gold ﬁlm changes and this is seen as an increase
in signal intensity. Resonance or response units (RU) are used to de-
scribe the increase in the signal, where 1 RU is equal to a critical
angle shift of 10−4 deg. At the start of the experiment all immobilised
receptor molecules have not been exposed to analyte molecules and
the RU value corresponds to the starting critical angle a. Analyte mol-
ecules are injected into the ﬂow cell; if they bind to the immobilised
receptor molecules, there is an association phase during which bind-
ing sites become occupied and the shape of this curve can be used to
measure the rate of association (kon). When steady-state is achieved
the RU value corresponds to the changed ﬁnal critical angle b. This
maximum RU value relates to the concentrations of immobilised re-
ceptor and analyte molecules and so can be used to measure the bind-
ing afﬁnity (KD). When analyte molecules are removed from the
continuous ﬂow there is a dissociation phase during which binding
sites become unoccupied and the shape of this curve can be used to
measure the rate of dissociation (koff). The surface can then be
regenerated and returned to the critical angle a to start the experi-
ment again. The lowest detectable concentration in the SPR experi-
ment depends on a number of factors including the molecular
weight, optical property and binding afﬁnity of the analyte molecule
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Fig. 1. Schematic illustration of the basic SPR experiment for measuring the binding of an analyte molecule to a receptor molecule. A. Instrument set up for an SPR experiment based
on BIAcore™ technology. SPR uses an optical method to measure the refractive index near to a sensor surface; this exploits total internal reﬂection of light at a surface-solution
interface to produce an electromagnetic ﬁeld or evanescent wave that extends a short distance (up to 300 nm) into the solution. The surface is a thin ﬁlm of gold on a glass support
that forms the ﬂoor of a small-volume (less than 100 nl) ﬂow cell through which an aqueous solution is continuously passed. In order to detect the binding of an analyte molecule to
a receptor molecule, the receptor molecule is usually immobilised on the sensor surface and the analyte molecule is injected in the aqueous solution through the ﬂow cell. Polarised
light from a laser source is directed through a prism to the under surface of the gold ﬁlm where surface plasmons are generated at a critical angle of the incident light. This absorp-
tion of light is seen as a decrease in intensity of the reﬂected light. The critical angle is dependent on the refractive index of the medium within 300 nm of the gold surface and
changes when molecules bind to the surface, e.g. when analyte molecules bind to immobilised receptor molecules. B. Change in the critical angle of incident light from angle a
to angle b on binding of an analyte molecule to a receptor molecule. C. Response of the SPR experiment in the form of a sensorgram. If interaction between the immobilised receptor
molecule and the analyte molecule occurs, the refractive index at the surface of the gold ﬁlm changes and this is seen as an increase in signal intensity. Resonance or response units
(RU) are used to describe the increase in the signal, where 1 RU is equal to a critical angle shift of 10−4 deg. At the start of the experiment all immobilised receptor molecules have
not been exposed to analyte molecules and the RU correspond to the starting critical angle a. Analyte molecules are injected into the ﬂow cell; if they bind to the immobilised re-
ceptor molecules, there is an association phase during which binding sites become occupied and the shape of this curve can be used to measure the rate of association (kon). When a
steady-state is achieved (all binding sites occupied in this example) the RU correspond to the changed ﬁnal critical angle b. This maximum RU relates to the concentrations of
immobilised receptor and analyte molecules and so can be used to measure the binding afﬁnity (KD). When analyte molecules are removed from the continuous ﬂow there is a
dissociation phase during which binding sites become unoccupied and the shape of this curve can be used to measure the rate of dissociation (koff). The surface can then be
regenerated and returned to the critical angle a to start the experiment again. (This ﬁgure was constructed based on pictures and information given in references [20,21,27,40]).
45S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55as well as the surface coverage of the receptor molecule. The SPR re-
sponse correlates with a change in mass concentration on the sensor
chip surface and therefore depends on the molecular weight of the
analyte molecule in relation to the number of receptor sites on the
sensor surface. If the term Rmax describes the maximum binding ca-
pacity of the surface receptor molecule for the analyte molecule in
RU, the theoretical Rmax is calculated using the equation Rmax =
(MWanalmol/MWrecmol) × Rrec × Vrec, where MWanalmol is the molecu-
lar weight of the analyte molecule, MWrecmol is the molecular weight
of the receptor molecule, Rrec is the response obtained from the re-
ceptor molecule and Vrec is the valency of the receptor molecule/
proposed stiochiometry of the interaction [37,38]. Achieving conditionswith an optimumRmax is important formeasuring the binding kinetics of
an interaction.
A range of ‘sensor-chips’ are commercially available for use with
SPR instruments allowing the user to immobilise their receptor mol-
ecule of interest to the gold surface [20,39–42]. For example, the
hydrophobic association (HPA) sensor chip contains long-chain
alkanethiol molecules covalently attached to the gold surface. Vesi-
cles are adsorbed on to the surface forming a supported lipid mono-
layer. Most chips other than HPA are based on carboxylated dextran
surfaces to allow preconcentration and/or chemistry to be performed.
For example, the L1 chip allows formation of lipid bilayers; its surface
has a dextran matrix modiﬁed with hydrophobic anchors enabling
46 S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55capture of vesicles that fuse and subsequently form a bilayer. Some
have functional groups (e.g. amino, thiol, aldehyde or carboxyl) to en-
able use of speciﬁc chemistry for the covalent immobilisation of re-
ceptor molecules on to the surface. If it is not possible to directly
immobilise the receptor molecule on to the surface, then a secondary
molecule such as an antibody can be used. An antibody that recog-
nises the receptor of interest is covalently immobilised on the surface
using speciﬁc chemistry then the receptor molecule is ‘captured’ on to
the surface by the antibody before exposure to analyte molecules.
Since the sensor chips can usually be regenerated after each experi-
ment, by washing off all analyte molecules, the same chip can be
used to test for binding of a number of different analyte molecules.
3. Challenges for characterising membrane protein–ligand
interactions using SPR
As with any structural or functional investigation with membrane
proteins, use of SPR to characterise their interaction with ligands re-
quires the protein to be in its original membranes or reconstituted
in a suitable membrane mimetic or solubilised in a suitable detergent
that retains the native structure, conformation and activity of the pro-
tein as far as possible. For characterisation of ligand binding, retaining
activity is obviously of most importance. This challenge usually has to
be combined with immobilisation or capture of the membrane pro-
tein on to the sensor surface. Some of the approaches that have
been developed to achieve this, which include covalent attachment
by selective chemistry and capture by antibodies or afﬁnity tags com-
bined with solubilisation and reconstitution strategies, are described
along with application to speciﬁc membrane protein systems in the
following section of this review.
Once the membrane protein is attached to the sensor surface, a
suitable ligand molecule has to be chosen for introduction into the
analyte ﬂow to test for protein activity. The choice of ligand molecule
will depend on the membrane protein system under investigation
and the aim of the intended experiments, e.g. screening a speciﬁc
binding site for ligand speciﬁcity. This should include appropriate
control experiments to show that the observed ligand binding activity
is speciﬁc, e.g. using a different membrane protein or a different li-
gand as a negative control. It may be useful to screen a range of
lipid reconstitution or detergent solubilisation conditions for the
membrane protein under investigation to identify those that give
the highest protein activity and stability. The measured ligand bind-
ing activity and speciﬁcity determined from the SPR experiment can
also be validated by applying other biochemical or biophysical tech-
niques to the membrane protein reconsitituted or solubilised under
similar conditions, e.g. using a radioligand binding assay. The struc-
tural integrity of the protein can also be tested in a similar way.
Such considerations are discussed along with application to speciﬁc
membrane protein systems in the following section of this review.
Having the membrane protein attached to the sensor surface under
lipid-reconstituted or detergent-solubilised conditions that retain the
active conformation of the protein is an important consideration. A rig-
orous demonstration of ligand binding and activity, as described above,
is a good indication of a membrane protein retaining its correct con-
formation. Further demonstration of a correct conformation can be
achievedby observing thebinding of conformation-dependent antibod-
ies to themembrane protein of interest. A homogenous surface with all
receptor molecules in the same orientation where the ligand binding
site is directed towards the analyte ﬂow rather than towards the sensor
surface is also an important consideration and should assist efﬁciency of
the experiment. This is achievable by capture methods that use afﬁnity
tags or antibodies where the receptormolecules are oriented by attach-
ment from a common site, but this does need prior knowledge about
the amino acid sequence and/or structure of the receptor molecule
under investigation. For some membrane proteins, access of the ligand
to both sides of the protein may be necessary to elicit the bindingresponse. This can be hindered if one side of the protein is used for at-
tachment to the sensor surface, so experimental systems have been de-
veloped that do allow access to both sides. These considerations are
described alongwith application to speciﬁc membrane protein systems
in the following section of this review.
Since the SPR effect is due to detection of amass change at the sensor
surface, where binding of larger molecules will produce a greater
change in refractive index, detecting the binding of small-molecule li-
gands is more challenging than for larger ones. Many membrane
protein ligands of interest, especially in drug discovery, are small mole-
cules with molecular weights of less than 1000 Da. The detection of
small-molecule ligands by SPR to membrane proteins is made easier
by having a high protein density on the sensor surface, but care has to
be taken that the protein is still active since a high density of denatured
protein is not very useful. When using the SPR experiment to screen a
number of ligands binding to a membrane protein attached to a sensor
surface, either directly or by competition with another ligand, it is im-
portant to have appropriate washing steps that regenerate the sensor
surface to its original condition and protein activity before introduction
of the next ligand. It is also important that the activity and stability of
the protein is retained for the duration of an experiment that screens
for the binding of a number of ligands using the same sensor surface.
This can be kept in check by performing appropriate activity and control
measurements throughout the experiment, including at the end. Condi-
tionswhere there isminimal time-dependent loss of protein activity are
obviously desirable. These are further challenges that have to be consid-
ered, some of which have been overcome as described alongwith appli-
cation to speciﬁc membrane protein systems in the following section of
this review.
4. Applications with membrane protein systems
4.1. GPCRs
The abundance and importance of GPCRs and their roles as drug
targets has been described in other contributions to this Special
Issue. SPR methods have been developed and used to characterise li-
gand binding with a number of GPCR systems, which are described in
this section.
4.1.1. Rhodopsin
Some of the earliest works that used SPR to detect and character-
ise binding to a GPCR, indeed to any membrane protein, were
performed on the light-activated receptor rhodopsin. Salamon et al.
incorporated bovine rhodopsin into an egg phosphatidylcholine bi-
layer deposited on a thin metal ﬁlm, in this case silver, and demon-
strated the tight binding and activation of its associated G-protein
(transducin) from the SPR data [43]. It was possible to monitor and
quantify the saturable binding of transducin to the receptor and
then follow effects from a light-induced conformational change and
then binding of GTP on its addition to the aqueous phase.
A few years later, spatially and time-resolved SPRmeasurements and
then amicropatterned immobilisation techniquewere developed [44,45]
to enable G protein activation, ligand binding, and receptor deactivation
with bovine rhodopsin to be followedby SPR (Fig. 2). The key to the latter
approach was use of microcontact printing to producemicrometer-sized
patterns that had high contrast in receptor activity compared with
the background and therefore enhanced sensitivity. Rhodopsin was
immobilised on the sensor surface by exploiting a glycosylation site at
the extracellular N-terminus that is conserved among GPCRs and use of
carbohydrate-speciﬁc chemistry for biotinylation (Fig. 2). Streptavidin
was bound to biotinylated-thiols in a mixed self-assembled monolayer
(SAM) with an excess of ω-hydroxy-undecanethiol (HTA) on the metal
surface, which then bound the biotinylated receptor to the surface
through its extracellular N-terminus in a deﬁned orientation (Fig. 2). Fol-
lowing immobilisation of the receptor and thorough washing with
NNNNN
α
GDPβ
αβ β
β αGDP β
α
GDP
α
GTP
GDP
GTP
Pi
hv
Gold film
Mixed SAM
Streptavidin
Biotinylated GPCR in a
supported lipid bilayer
G protein
(i) (ii) (iii) (iv) (v)
N
A
B C D
Au
Streptavidin Rhodopsin Rhodopsin
Streptavidin
HTA Biotinthiol
Oxidised
glycosylation
site
Biotin
hydrazide
N
+
N
C Hydrazone
bond
( )10
γ γ
γ
γ γ
H
N
N
H
O
s
OH
O
S
NH
S
HN
O
O
O
H O
H2N
NH
O
O
N
N
H
H
S
NH
O
N
H
N
O
N
H
S
Fig. 2. Immobilisation of rhodopsin for monitoring G protein activation, ligand binding and receptor deactivation events by SPR. A. (i) On a gold ﬁlm coated with a mixed SAM of
biotinylated-thiols with an excess of ω-hydroxy-undecanethiol (HTA), streptavidin is bound which then binds the receptor through a carbohydrate-speciﬁc biotinylation site at its
N-terminus. A supported lipid bilayer is then formed around the immobilised receptor, which binds the G-protein. (ii) Light-induced photoisomerisation of receptor-bound 11-cis
to all-trans-retinal triggers the active conformation of rhodopsin, which binds the G-protein releasing its GDP. (iii) The G-protein desorbs from the receptor upon GTP binding.
(iv) The activated receptor decays spontaneously to all-trans-retinal and opsin and the G-protein binds again to the membrane surface following hydrolysis of GTP. (v) cis-retinal
binds to opsin, which regenerates photoactivatable rhodopsin. B. Expansion of the arrangement on the sensor surface with hatched boxes highlighting the regions expanded further in
C and D along with details of the surface chemistry. C. Mixed SAM of HTA and the biotinylated thiol 12-mercaptododecanoic-(8-biotinoylamido-3,6-dioxaoctyl)amide, which are cova-
lently attached to the gold surface through their sulphur atom; the latter binds streptavidin through its biotin group. D. A glycosylation site on the extracellular N-terminus of rhodopsin
is oxidised and then reactedwith biotin hydrazide to form a hydrazone bond; the biotinylated receptor is then bound to streptavidin that is already attached to the preformed SAMon the
sensor surface. (This ﬁgure was constructed based on a picture and information given in Bieri et al. [45]).
47S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55detergent (48 mM), a supported lipid bilayer (SLB) [46] was formed
around the receptors by use of a detergent micellar dilution method
[47]. This involved treatment with an aqueous solution of 0.1 M KCl
containing 50 mM the detergent octyl glucoside and 4 mM of phospha-
tidylcholine lipid. Formation of the lipid layer was achieved by stepwise
dilution of the detergent in the analyte ﬂow to below its CMC value and
until the SPR response was stable. Having this lipid layer supported on
top of the preformed SAM provides a water layer between the two; this
is important for accommodating the proper folding of extramembrane
parts of the reconstituted receptor. Micropatterns of SAMs on the metal
surface with alternating stripes (width 200 μm) of pure HTA (back-
ground reference) and biotin-thiol/HTA (receptor binding region) were
produced followed by the binding procedure described above. Activity
of the immobilised receptor was observed in SPR data following its illu-
minationwith light,whichwas achieved by use of home-built SPR equip-
ment where a glass window at the opposite side of the cuvette allowed
for ﬂash illumination of the surface (see reference [44] for a diagram of
the optical conﬁguration). Illumination induced activity of the G protein
was followed by its desorption from the membrane (Fig. 2A, (ii) and
(iii)); this activity was twenty ﬁve times lower in the reference region
of the micropattern. Following activation, the SPR data could also then
follow cleavage of the Schiff's base between rhodopsin and its chromo-
phore all-trans-retinal and relaxation of the G protein to its starting posi-
tion (Fig. 2A, (iv) and (v)). Ligand bindingwasmonitored and quantiﬁed
from the SPRdata by adding 11-cis-retinal in increasing concentrations tothe immobilised and completely photolysed receptor (opsin), which
gave a dissociation constant of 130 nM.
In further experiments using rhodopsin as amodel protein, Karlsson
and Löfås developed a rapid ﬂow-mediated on-surface immobilisation
and reconstitutionmethod for SPRmeasurements withmembrane pro-
teins [48]. This used a carboxylated dextran surface modiﬁed with
long alkyl groups (L1 chip) to which detergent-solubilised puriﬁed
receptorwas immobilised by amine-coupling. The surfacewas immedi-
ately washed with lipid/detergent (POPC/octylglucoside) mixed mi-
celles then the detergent was eluted in the subsequent buffer ﬂow
and the remaining lipid formed a bilayer on the sensor surface, which
reconstituted the receptor. Activity of the reconstituted receptor was
demonstrated by monitoring the rhodopsin-mediated dissociation of
transducin. Since the reconstitution procedure could be achieved in ap-
proximately 1 minute and the deposited lipids could be completely re-
moved by two consecutive injections of detergent, this method offered
potential for medium-throughput measurements with membrane pro-
teins that are stable to the procedure.
4.1.2. Chemokine receptors CCR5 and CXCR4
SPR has been used to characterise ligand binding to the human
chemokine receptors CCR5 and CXCR4. These receptors have also
been used to demonstrate important developments in SPR methods
for puriﬁcation, solubilisation, reconstitution and functional analysis
of GPCRs. Hüttenrauch et al. used SPR to investigate the location of
48 S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55β-arrestin 1 binding to CCR5, which was shown to be at a conserved
Asp-Arg-Tyr motif within the second intracellular loop [49]. This
work used C-terminal derived peptides and a cytoplasmic loop of
CCR5 immobilised on a CM5 sensor chip through the thiol group of
an N-terminal cysteine residue or on a Sa5 streptavidin sensor chip
through an N-terminal biotin moiety, repectively. β-Arrestin 1 was
included in the analyte ﬂow for analysis of its binding from the SPR
response.
Using CCR5 and CXCR4 as model systems, Stenlund et al. [50] devel-
oped amethod for the capture and reconstitution of GPCRs on to a sensor
surface from crude cell preparations without the need for their prior pu-
riﬁcation (Fig. 3A). The ‘capture and reconstitution’methodﬁrst involves
immobilisation of a capturingmolecule that recognises the GPCR at a site
distinct from the ligand binding site, in this case 1D4 monoclonal
antibodies were immobilised through aldehyde coupling chemistry to
a hydrazide-modiﬁed L1 sensor chip. Detergent-solubilised receptorsA
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Fig. 3. Capture and reconstitution of GPCRs on a biosensor surface: Binding of conformation
and CCR5. A. Schematic illustration for the capture and reconstitution of GPCRs on a sensor s
ligand binding site, in this case 1D4 monoclonal antibody, is immobilised on an L1 se
detergent-solubilised GPCR is captured by the immobilised antibody. (iii) The captured GP
analyte ﬂow. (iv) The surface is washed with buffer to remove detergent molecules, leaving
ed by binding of conformation-dependent antibodies. (vi) Binding of small-molecule ligands
the capture and reconstitution of CXCR4 and CCR5 receptors in POPC lipids on an L1 sensor
1D4 antibody, conformation-dependent monoclonal antibodies (12G5, 44716.111, 44717.1
receptors captured and reconstituted in POPC lipids on an L1 chip. D. Sensorgrams illustra
20, 40, 80, 160, 320, 640 nM) to CXCR4 captured and reconstituted in POPC lipids on an L1
by the small-molecule TAK-779 (10 μM) and the 2D7 monoclonal antibody (156 nM), where
illustration of the capture and reconstitution method for measuring the binding of conformati
CCR5. (Pictures A–D are modiﬁed from Stenlund et al. [50], E is modiﬁed from Navratilova et afrom crude cell lysates are then captured by the antibody molecules on
to the sensor surface. Washing with lipid/detergent mixed micelles, in
this casemade of POPC/CHAPSO, reconstitutes the receptors in a lipid bi-
layer fromwhich detergent is removed by washing with buffer (Fig. 3B)
[50]. The captured and reconstituted receptors can then be tested for ac-
tivity and for the binding of ligands. Both CCR5 andCXCR4were captured
in this way then the structural and functional integrity of CXCR4 was
tested by the binding of a conformationally-dependent antibody and a
native chemokine ligand stromal cell-derived factor 1α (SDF-1α)
(Fig. 3C and D) [50]. Having the receptor molecule attached to the anti-
body at a known site that is distinct from the ligand binding site helps
to orient the receptor so that the ligand binding site is facing towards
the analyte ﬂow rather than towards the sensor surface and should
also create a more homogenous surface. Interestingly, binding of
SDF-1α to CXCR4 captured and reconstituted on an L1 chip, captured
on an L1 chip without lipids and captured on a CM5 chip gave similarB
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-dependent antibodies and small-molecule ligands to the chemokine receptors CXCR4
urface. (i) A capturing molecule that recognises the GPCR at a position distant from the
nsor chip that has a dextran surface containing hydrophobic alkane groups. (ii) A
CR is reconstituted in a lipid bilayer by injecting lipid/detergent-mixed micelles in the
behind a lipid bilayer. (v) The functional activity of the lipid-reconstituted GPCR is test-
by the captured and reconstituted GPCR can then be tested. B. Sensorgrams illustrating
chip from detergent-solubilised Cf2Th cells. C. Sensorgrams illustrating the binding of
11) and anti-CCR5 antibody 3A9 to control, CXCR4 and CCR5 sensor surfaces with the
ting the binding of chemokine SDF-1α at a range of concentrations (0, 1.25, 2.5, 5, 10,
sensor chip. E. Sensorgrams illustrating the inhibition of gp120/CD4 binding to CCR5
responses are compared with uninhibited binding of gp120/CD4 (100 nM). F. Schematic
on-dependent antibodies and small-molecule ligands to chemokine receptors CXCR4 and
l. [51] and F is reproduced from Navratilova et al. [52]).
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4 nM, respectively, whichwere also similar to a value of ~200 nMdeter-
mined from a cell-based assay. This demonstrates that a membrane pro-
teinmay not have to be in amembrane or lipid environment to retain its
ligand binding activity, solubilsation in detergent may be sufﬁcient; this
has to be tested on a case by case basis with each membrane protein
under investigation. The same groupmade a number of further develop-
ments to themethod and successfully demonstrated its use for screening
small-molecule binding. An automated BIAcore™-based assay was de-
veloped for screening receptor solubilisation conditions to improve re-
ceptor activity and stability, which was demonstrated with CCR5 and
CXCR4 [51]. This work also demonstrated that CCR5 was functional
with respect to binding the HIV-1 viral surface protein gp120, which
was inhibited by the small molecule TAK-779 (Fig. 3E) [51]. The system
was then used to screen for further small molecule binding (Fig. 3F)
[52], as follows. CCR5 and CXCR4 were captured by 1D4 immobilised
on a CM4 sensor chip using amine-coupling chemistry and their activi-
ties were demonstrated by binding of the native chemokine ligands
RANTES and SDF-1α, respectively. Nineteen small-molecule inhibitors
(averageMW550 Da) at a range of concentrations were tested for bind-
ing to CCR5 using freshly prepared sensor surfaces. The resultant binding
afﬁnities (KD values) from the SPR measurements showed good correla-
tion with inhibition constants (Ki values) obtained from a whole-cell
based assay that tested binding of the same compounds [52]. This work
therefore demonstrated the potential for using SPR to screen
small-molecule libraries of compounds for their binding to GPCRs.
In the same year, Silin et al. reported an alternative method for
capturing GPCRs on a sensor surface using CCR5 as a model [53].
This involved selective immobilisation of receptor-containing mem-
brane vesicles on a sensor surface that was constructed from sequen-
tial treatments of biotin in a protein-resistant matrix with (strept)
avidin, a biotinylated antibody, and a receptor-speciﬁc antibody.
The automated BIAcore™ technologywas also used to develop an af-
ﬁnity puriﬁcation method and a screen for co-crystallisation conditions
with CCR5 [54]. This work included characterisation of nine HIV-1
gp120 variants and identiﬁed a truncated construct that bound CCR5 in-
dependent of CD4, which was then used in an afﬁnity puriﬁcation step
to improve activity of the detergent-solubilised receptor by approxi-
mately 300% [54]. Automated systems for detergent screening of
GPCRs were also developed using CCR5 [55]. The developed SPR
methods with CCR5 have been used to measure the real-time binding
of gp120 and to identify antagonists that bind to the receptor and stabi-
lise a conformation that is unable to bind the HIV-1 gp120–CD4 com-
plex [56] and to screen for the binding of novel orthosteric and
allosteric ligands [57]. In recent work that demonstrated CCR5 to be a
receptor for Staphylococcus aureus leukotoxin ED [58], SPR was used
to show a direct interaction between the LukE subunit and CCR5 in
whichbindingwas time-dependent and saturablewith an apparent dis-
sociation constant (KD) of 39.6 ± 0.4 nM. An inability of LukE to bind to
CXCR4 conﬁrmed the binding to CCR5 to be speciﬁc.
4.1.3. Neurotensin receptor-1
A novel receptor-analyte conﬁguration was used to characterise
neurotensin receptor-1 binding to the neurotransmitter peptide
neurotensin using SPR [59,60]. Neurotensin biotinylated at the
N-terminus was immobilised on a streptavidin-coated sensor chip and
puriﬁed detergent-solubilised receptor was included in the analyte
ﬂow for analysis of the receptor-ligand interaction. The reasoning be-
hind this arrangement was that binding of the larger receptor molecule
to the immobilised ligand would produce a greater mass change on
binding and therefore a larger SPR response. AnN-terminal biotinylated
‘scrambled’ peptide with the same residues as neurotensin was
used to create a control sensor surface for receptor binding. A speciﬁc
concentration-dependent ligand-receptor interaction was demonstrat-
ed from the SPR data, which yielded an apparent KD value of 1–2 nM
similar to values measured using a radioligand-binding assay.4.1.4. Human olfactory receptor 17-4
SPR has been used to demonstrate the ligand binding activity of a
human olfactory receptor produced by cell-free synthesis [61].
Human olfactory receptor 17-4 (hOR17-4) was captured by a mono-
clonal anti-polyhistidine antibody immobilised on a CM4 sensor
chip using amine-coupling chemistry. The odorant undecanal was
injected at a range of concentrations and the resultant SPR response
was used to derive a binding afﬁnity of ~22 μM, which was in agree-
ment with measurements obtained from other in vitro techniques.
4.1.5. Neuropeptide Y4 receptor N-terminal domain
As part of structural and functional studies of the 41-residue
N-terminus of the neuropeptide Y4 receptor (N-Y4), SPR was used to
investigate possible interactions with peptides from the neuropeptide
Y (NPY) family [62]. N-terminal biotinylated neuropeptides were
immobilised on a streptavidin-coated sensor chip and N-Y4was injected
in the analyte ﬂow at a range of concentrations. The SPR response gave a
KD value of 50 μM for binding of the natural ligand pancreatic polypep-
tide (PP), whilst binding of the hormones neuropeptide Y (NPY) and
peptide YY (PYY) was too weak to measure an afﬁnity (>1 mM).
4.1.6. Adenosine-A2A receptor
Using the adenosine A2A receptor, a new approach called ‘Biophys-
ical Mapping’ (BPM) [63,64] has been developed that combines a
thermostabilised GPCR with SPR analysis of ligand binding to
binding-site mutants to give matrices of data that can be used to pro-
duce high quality three-dimensional pictures of ligand binding sites
in the absence of a high-resolution crystal structure or can be com-
bined with such a structure (Fig. 4). A stabilised form of the A2A re-
ceptor, ‘StaR’ was engineered by introducing a number of mutations,
which included A54L, T88A, K122A and V239A following alanine-
scanning mutagenesis. Further single-site mutations were introduced
into this StaR background at eight positions (L85A, L167A, M177A,
N253A, Y271A, I66A, N181A, S277A) predicted to be directly involved
in ligand binding from a homology model based on the crystal struc-
ture of the thermostabilised β1-adrenergic receptor and from the re-
sults of radioligand binding with the antagonist [3H]ZM241385.
Each of the detergent-solubilised StaR mutants was immobilised on
a Ni-loaded NTA sensor chip through their His-tag and tested for
binding with a library of 21 small-molecule compounds that were
injected separately in the analyte ﬂow at a range of concentrations
(5–80 nM). The SPR responses (Fig. 4B) were used to create matrices
of binding afﬁnities and kinetic information (KD, kon, koff) to compare
the effects of each mutation on ligand binding speciﬁcity (Fig. 4C).
Binding afﬁnities measured for each compound with the unaltered
StaR background were very similar to those obtained from a compet-
itive radioligand-binding assay. The structure-activity relationships
observed in the SPR data were used to create biophysical maps and
to optimise homology models of the A2A receptor binding site with
docked ligands (Fig. 4D and E). A subsequent crystal structure of the
A2A receptor in complex with ZM241385 [65] allowed testing of the
homology model with this ligand that was revised based on the
BPM experiments. The binding pose of the ligand was very similar
in the crystal structure and model except for a difference in the chi1
angle of Tyr271. A later crystal structure solved for an A2A StaR in
complex with ZM241385 [66] had a more similar conformation for
Tyr271 compared with the BPM-derived homology model, however.
This work has demonstrated how SPR can be used to screen a li-
brary of small-molecule ligands for binding to a real GPCR and how
the resultant binding and kinetic data can be used to create a
three-dimensional picture of the ligand-binding site.
4.1.7. β1-Adrenergic receptor
A biophysical fragment screening approach using SPR for the ini-
tial screen has recently been applied to the thermostabilised turkey
β1-adrenergic receptor (β1AR) [67]. Alongside the thermostabilised
StaR L85A
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A2AStaR Binding of compound ZM241385 21 compounds binding to 7 mutants
Biophysical map for ZM241385Docking model for ZM241385
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K D
Fig. 4. Biophysical mapping of the adenosine A2A receptor using SPR. A. The procedure starts with a stabilised receptor (StaR) minimally engineered for thermostability.
B. Sensorgrams for binding of compound ZM241385 to StaR and mutant forms of A2A. Following introduction of further single mutations at positions proposed to be in the ligand
binding site, SPR measurements of ligand binding are performed on the StaR and mutant receptors. C. Matrix of SPR responses (as a log difference compared with unaltered
StaR background) for 21 compounds binding to 7 different mutants of A2A. D. Biophysical representation from the SPR data for compound ZM241385 based on a homology
model of A2A. Each of the shown residues was mutated to alanine and the log difference value for binding compound ZM241385 is shown. Key: residues in bold font = in front
of the plane, italics = behind the plane, normal font = in the plane of the ligand, NB = non-binding, black oval = largest effect, dotted circle = second largest effect, shaded
box = third largest effects. E. Docked structure of compound ZM241385 in a homology model of A2A. Asn 253 is coloured red as mutation of this residue prevents binding of ligands.
The ﬁrst, second and third tier effects of mutations are coloured according to the key and relate to the residues indicated in D from the BPM data. (Picture A was produced using the
PDB ﬁle (PDB ID: 3PWH) and PDB Protein Workshop 3.9 fromMoreland et al. 2005; B was modiﬁed from Zhukov et al. [63]; C was constructed from data given in Zhukov et al. [63];
D and E were reproduced from Zhukov et al. [63]).
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subset of the Heptares fragment library (~650 fragments) using SPR
with the receptors immobilised on nickel-charged NTA sensor chips.
Among the fragments that bound selectively to β1AR StaR were two
arylpiperazine compounds with binding afﬁnities (KD values) of 16
and 5.6 μM and good ligand efﬁciencies of 0.41 and 0.48 (Fig. 5A). A
fragment hit-to-lead exercise was then performed using a radioligand
binding assay, which identiﬁed a number of fragments that bound
with even higher afﬁnity including an indole compound and a quino-
line compound (Fig. 5B). Crystal structures of thermostabilised β1ARA B
(i) (ii) (i) (ii)
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Fig. 5. High afﬁnity ligands for the β1-adrenergic receptor identiﬁed by biophysical
fragment screening. A. Arylpiperazine compounds with binding afﬁnities (KD values)
of 16 and 5.6 μM for (i) and (ii), respectively, identiﬁed by SPR screening of a fragment
library against thermostabilised turkey β1AR. B. (i) Indole and (ii) Quinoline com-
pounds identiﬁed as higher afﬁnity ligands of β1AR from a fragment hit-to-lead exer-
cise using a radioligand binding assay based on the compounds shown in A. (These
chemical structures were taken from Christopher et al. [67]).in complex with these two compounds were solved at resolutions of
2.8 and 2.7 Å, respectively. The observed protein–ligand interactions
in the crystal structures suggested that these compounds are antago-
nists of β1AR. These results demonstrate a ﬁrst full fragment-based
drug discovery program applied to a GPCR with screening using SPR.
4.2. Non-GPCRs
In addition to GPCRs, SPR methods have been developed and used
to characterise ligand binding with a range of other membrane pro-
tein systems, which are described below.
4.2.1. Outer membrane receptor FhuA
SPR has been used to probe for conformational changes in the
FhuA outer membrane receptor of E. coli, which transports iron-
chelating siderophores into the cytoplasm, by observing the binding
of monoclonal antibodies [68]. These measurements were performed
with FhuA in its apo- and siderophore-bound states with ferricrocin
and in the absence and presence of protein TonB, which is found in
the cytoplasmic membrane and transduces energy to FhuA to facili-
tate siderophore transport. Four monoclonal antibodies were pro-
duced that mapped to epitopes on outer surface-exposed loops 3, 4
and 5 and to β-barrel strand 14. For measurements of antibody bind-
ing to FhuA, the antibodies were immobilised separately on CM4 sen-
sor chips using amine coupling chemistry and FhuA was injected in
the analyte ﬂow. For measurements involving TonB, this protein
was immobilised on the sensor chip using thiol coupling chemistry
followed by injection of FhuA and then the antibodies. SPR data was
51S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55used to measure the kinetics of all binding interactions, which re-
vealed that binding of TonB to FhuA promotes conformational
changes in outer surface-exposed loops 3 and 5 of FhuA. The data
also suggested that the presence of ferricrocin alters the properties
of the FhuA-TonB binding interaction and therefore inﬂuences the re-
sultant conformational changes.
4.2.2. Tyrosine kinase HER2 receptor subdomain
Using the tyrosine kinase receptor HER2 as a proof of principle, a
medium-throughput ligand screening strategy has been developed
using synthetic peptides that mimic a selected subdomain of the
target protein [69]. In this case, a modiﬁed fragment that mimics HER2
domain IV in its Herceptin-bounded conformation was designed and
immobilised using a biotinylated N-terminus on a streptavidin-coated
sensor chip. Injection of the antibody Herceptin in the analyte ﬂow at a
range of concentrations produced SPR responses from which the mea-
sured binding afﬁnity (KD 19.2 nM) and kinetic rate constants veriﬁed
the approach for SPR analysis of ligand binding.
4.2.3. Human (pro)renin receptor
SPR has been used to investigate binding of human (pro)renin re-
ceptor to human renin with the receptor in three forms: full-length
(hPRR), lacking the cytoplasmic domain (hPRR-ΔCD) and just the ex-
tracellular domain (hPRR-ΔTMΔCD) [70]. Puriﬁed human renin was
immobilised on a sensor chip using amine coupling chemistry then
the three puriﬁed receptor forms injected in the analyte ﬂow at a
range of concentrations. The SPR data showed binding afﬁnities for
full-length hPRR and hPRR-ΔCD of 46 and 330 nM, respectively,
suggesting that the cytoplasmic domain of hPRR is not essential for
the binding of renin. The hPRR-ΔTMΔCD form showed no binding af-
ﬁnity, therefore demonstrating that the puriﬁed hPRR extracellular
domain does not have the ability to bind with human renin. Extracel-
lular domain obtained from the microsomal fraction (non-puriﬁed)
did retain full renin binding activity compared with full-length
hPRR, however.
4.2.4. α-Hemolysin
Using α-hemolysin and binding of its speciﬁc antibody as a model
system, a novel SPR approach using arrays of periodic nanopores in a
free-standing metal ﬁlm and pore-spanning lipid membranes has
been developed for kinetic binding assays [71] (Fig. 6). This differs
from conventional SPR since it is based on the phenomenon of an ex-
traordinary optical transmission (EOT) effect [72] through periodic
nanopore arrays in metallic ﬁlms (Fig. 6A), in this case using an Au/
Si3N4 ﬁlm. The patterned nanopores in the metal ﬁlm are encapsulat-
ed in a silica layer then a pore-spanning lipid membrane is formedFig. 6. Detection of antibody binding toα-hemolysin using a plasmonic nanopore array and p
ﬁlm with a pore-spanning lipid membrane. The transmission of light through the nanopores
sequent binding of molecules. The lipid membrane is suspended over the nanopores such t
brane. B. Transmission spectra change before (black line) and after formation of a pore-sp
membrane (green line) and after binding of anti-α-hemolysin antibody (blue line) on a Au
anti-α-hemolysin antibody binding at a range of concentrations to α-hemolysin in a suspe
al. [71]).over the surface by vesicle rupture. Since part of the lipid membrane
is suspended over the nanopores it is accessible from both sides and
therefore better resembles a natural lipid membrane. A target protein
can be reconstituted into the lipid membrane and the binding of li-
gands changes the local refractive index and the EOT effect through
the nanopores. In the transmission spectra, the resonance wavelength
red-shifted on forming the lipid membrane from phosphatidylcholine
vesicles and then shifted further on incorporation of heptameric
α-hemolysin into the lipid membrane and then further again on
binding biotinylated anti-α-hemolysin antibody (Fig. 6B). Real-time
kinetic measurements were made to follow these events and then
to monitor the binding of a range in concentrations of the antibody
(Fig. 6C) and the response used to measure a binding afﬁnity (KD)
of 19 ± 10 nM. Binding of streptavidin-R-phycoerythrin to the anti-
body further conﬁrmed the speciﬁc binding interaction of the anti-
body with α-hemolysin.
4.2.5. β-Site amyloid precursor protein cleaving enzyme 1
An SPR ligand binding assay for full-length β-site amyloid precur-
sor protein cleaving enzyme 1 (BACE1) reconstituted in native brain
lipid membranes has been developed [73]. This protein, which has a
single transmembrane-spanning domain, is responsible for control-
ling the formation of peptides that are constituents of amyloid
plaques, so it is therefore a drug target for Alzheimer's disease.
BACE1 was expressed in insect cells and captured directly from the
cell lysate on to an L1 sensor chip surface immobilised using amine
coupling chemistry with an antibody speciﬁc for a His6 tag. The pro-
tein was then reconstituted into a membrane formed from brain
lipid extract and tested for the binding of six different known
BACE1 inhibitors. This analysis was performed using two different
pH values of 7.4 and 4.5 and in the presence of added calcium. Kinetic
analysis of the SPR responses showed different binding characteristics
for the different compounds and at the different pH values, the addi-
tion of calcium had no signiﬁcant affects on these.
4.2.6. Human CD4 receptor in nanodiscs
Using the human CD4 receptor as a model system, a new SPR ap-
proach with membrane proteins reconstituted in nanodiscs as the ana-
lyte has been developed for ligand-binding studies [74]. Nanodiscs are
discoidal model membrane systems that can encapsulate and solubilise
integral membrane proteins in a near-native environment and have al-
ready been used with a number of biophysical techniques. This work
used a cysteine replacement variant of the transmembrane and cyto-
plasmic domains (residues 372–433) of human CD4 fused to ubiquitin
with a His10 tag at its N-terminus referred to as His-Ubi-CD4. Nanodiscs
containing this fusion protein were constructed using a membraneore-spanning lipid membrane. A. Cartoon representation of a nanopore array in a metal
is modulated by the presence of a lipid membrane formed by vesicle rupture and sub-
hat it can be accessed from both sides and therefore better mimics a natural cell mem-
anning lipid membrane (red line), after formation of a α-hemolysin pore on the lipid
/Si3N4 ﬁlm with a periodic array of nanopores. C. Real-time kinetic measurements for
nded lipid membrane on a nanopore array. (Pictures A–C were reproduced from Im et
52 S.G. Patching / Biochimica et Biophysica Acta 1838 (2014) 43–55scaffold protein (MSP) and POPC lipids with isolation and puriﬁcation
by gel ﬁltration chromatography and solutions of these were used as
the analyte in the SPR measurements. The resultant nanodiscs
contained one His-Ubi-CD4 molecule per nanodisc. For binding to a
PentaHis monoclonal antibody immobilised on a CM5 sensor chip
through amine coupling, control analyte solutions contained His-Ubi
(not fused to CD4) or empty nanodiscs. Measurements with empty
nanodiscs were subtracted from measurements with His-Ubi-CD4-
nanodiscs to correct for any background non-speciﬁc binding. Kinetic
analysis of SPR data obtained using a range in analyte concentrations
gave afﬁnities and rate constants in the expected range with KD values
of 10 and 11 nM for binding His-Ubi and His-Ubi-CD4-nanodiscs, re-
spectively. This work demonstrated that it is feasible to use membrane
proteins solubilised in nanodiscs as the analyte for SPR measurements
of ligand binding.
4.2.7. Human ABC transporter P-gp in nanodiscs
SPR has been used to probe the conformation of humanATP-binding
cassette transporter P-gp reconstituted in lipid nanodiscs and the bind-
ing of inhibitory antibodies [75]. P-gp mediates the efﬂux of drugs
that contributes to cancer cell drug resistance, so is a target for new
therapeutics that modulates the effectiveness of such drugs. The anti-
bodies MRK16 and UIC2 were immobilised separately on CM5 sensor
chips using amine-coupling chemistry. Puriﬁed P-gp reconstituted in
MSP1D1 nanodiscs was injected in the analyte ﬂow in the absence
and presence of the drug vinblastine and the non-hydrolysable nucleo-
tide AMPPNP andwith ADP or ADP plus VO4. P-gpwas shown to bind to
both antibodies in the absence of drug and in the presence of AMPPNP
or AMP. The afﬁnity and kinetics for binding of the P-gp nanodiscs
to the antibodies were not affected by the presence of vinblastine.
The results also suggested that drugs are not released from the
ADP-VO4-trapped state.
4.2.8. Epidermal growth factor receptor on intact cells
A novel intact-cell-based SPR method for measurements of ligand
binding has been developed and demonstrated with the epidermal
growth factor (EGF) receptor [76]. The peptide ligand EGF was
biotinylated using a polyethylene glycol spacer by coupling with its
amine groups and then immobilised on a streptavidin-coated sensor0
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Fig. 7. Screening of ligand binding by full-length homo-oligomeric β3 γ-aminobutyric acid t
GABAergic ligands that showed a binding effect when injected at a range of concentration
(GABAA) receptors captured on a sensor chip. Inset are the sensorgrams for binding of h
state signals plotted as a function of concentration with a ﬁtted Langmuir binding isother
also shown. (The bar-chart was constructed from data given in Seeger et al. [77]; the sensochip. A suspension of human carcinoma A431 cells was injected in
the analyte ﬂow and the resultant SPR responses were consistent
with binding to the immobilised EGF. The speciﬁcity of the interaction
was conﬁrmed by competitive reduction of this response by the free
EGF ligand added at a range of concentrations in the analyte ﬂow
along with the cells.
4.2.9. β3 γ-aminobutyric acid type A receptors
An SPR assay has been used to screen the binding of 51 histaminer-
gic and 15 GABAergic ligands with full-length homo-oligomeric β3
γ-aminobutyric acid type A (GABAA) receptors [77] (Fig. 7), which be-
long to the superfamily of Cys-loop ligand-gated ion channels and
are involved in a wide range of neurological functions. Though the
homo-oligomeric forms of these receptors have not yet been identiﬁed
in the human brain, they serve as usefulmodel systems for investigating
receptor function and pharmacology [77]. This work used rat homo-
oligomeric β3 GABAA receptors with a His8-tag that were expressed in
insect cells, puriﬁed from isolated membranes and solubilised in deter-
gent. The receptors were captured by polyhistidine monoclonal anti-
bodies that were immobilised on CM3 and CM5 sensor chip surfaces
using amine coupling chemistry, a control ﬂow cell had a surface with
immobilised antibodieswithout bound receptors. Ligandswere injected
at a range of concentrations with a 2-fold dilution series in the analyte
ﬂow. Equilibrium dissociation constants (KD) were determined by
non-linear regression analysis of steady-state SPR signals as a function
of ligand concentration using a Langmuir isotherm equation. In addition
to direct interaction binding of ligands with the receptors, competitive
bindingwith histaminewas alsomeasured for amore rigorous analysis.
Of the 51 histaminergic ligands tested, 17 had a binding interaction
with a KD value of less than 300 μM (Fig. 7). Despite its small size, bind-
ing of histamine could be detected giving a KD value of 100 μM,which is
in the sameorder ofmagnitude as values obtained fromelectrophysiolog-
icalmeasurements onhumanhomo-oligomeric receptors [77]. Histamine
H1 receptor ligands did not interact with the β3 receptors, binding of
histamine H2 receptor agonists, except histamine, was not detected,
whilst three histamine H2 receptor antagonists bound with a higher af-
ﬁnity than histamine (tiotidine, burimamide and famotidine). Some his-
tamine H3/H4 receptor ligands showed binding to the β3 receptors, ﬁve
with a higher afﬁnity than histamine (agonists (S)-α-methylhistamine,Fa
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istamine injected in a 2-fold dilution series from 1000 to 8 μM (left) and the steady
m, which gave a binding afﬁnity (KD) of 98 μM (right). The structure of histamine is
rgrams and binding curve were reproduced from Seeger et al. [77]).
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Some histamine H4 receptor ligands also bound to the receptors with a
higher afﬁnity than histamine, including 4-methylhistamine (Fig. 7). Of
the 15 GABAergic ligands tested, ﬁve known active compounds showed
a binding interaction with the β3 receptors of higher afﬁnity than that
of histamine, but still in the low micromolar range (Fig. 7), whilst the
others showed no binding up to a concentration of 100 μM. In the com-
petitionmeasurements, thirteen of the active histaminergic ligands com-
peted with histamine whilst none of the GABAergic ligands showed a
competitive effect. This work not only conﬁrmed that GABAA receptors
havedistinct histaminergic pharmacology in agreementwithprevious re-
sults, it also identiﬁed new ligands of the β3 receptor. It is noteworthy
that 200 ligand injections on a single sensor surface in ~20 h was possi-
ble; this is sufﬁcientlymedium-throughput to enable screening for higher
afﬁnity ligands with potential as histaminergic drugs by fragment-based
drug discovery.
5. Recent developments and potential for drug discovery
Next-generation SPR instruments use a sensor surface based on
nano-structured materials [78] (Figs. 6 and 8A). Unlike the BIAcore™
technology, which uses a prism to focus the light, these instruments
are based on the phenomenon of extraordinary optical transmission
(EOT) [72] where light at speciﬁc wavelengths transmitted through
nanoholes in thin metal ﬁlms is of higher intensity than the incident
light. This is a consequence of plasmon generation in the metal ﬁlm.A
B
Plasmon generation throu
Surface plasmon resonan
(i)
Fig. 8. Next-generation SPR instrumentation for measuring membrane protein–ligand bind
due to plasmon generation which undergoes a red-shift on binding of molecules. B. Surface
experimental set-up; (ii) SPR image of a cell; (iii) ﬂuorescence image of a cell; (iv) bright-ﬁe
from Wang et al. [80]).When a large number of nanopores are arranged in a periodic array in
a metal ﬁlm, their combined plasmon generation ‘funnels’ the light en-
ergy across the ﬁlm.Whenmolecules bind to themetal surface the spe-
ciﬁc wavelength of light for optimum transmission is shifted, so the
surface can be used as a sensor. Due to the large number of nanopores
that can be patterned in to the metal ﬁlm, the sensing capability of
this approach is much greater than can be achieved by a conventional
SPR instrument. Furthermore, a lipid bilayer can be suspended above
the nanopores and contain amembrane protein of interest. Since the bi-
layer can be accessed from both sides of the pore, this now allows SPR
analysis of ligand binding to membrane proteins in a more native or
near-native environment. This type of approach was demonstrated
withα-hemolysin binding to its speciﬁc antibody described earlier [71].
An exciting new technique called surface plasmon resonance mi-
croscopy (SPRM) has recently been demonstrated that enables mea-
surement of binding kinetics of membrane proteins in single living
cells and therefore in their true native membrane environment
[79,80] (Fig. 8B). The technique also allows the simultaneous mea-
surement of optical and ﬂuorescence imaging of the same sample.
Cells are cultured on a gold-coated slide and SPRM imaging is
performed using an inverted microscope. Binding of ligands to recep-
tor proteins on the cell surface can be monitored by SPRM with milli-
second temporal and micrometer spatial resolution. So far this
technique has been used to measure the binding interaction between
glycoproteins on the cell surface and lectin injected as analyte and the
binding activity and spatial distribution of nicotinic acetylcholinegh nanopores
ce microscopy
(ii)
(iii)
(iv)
ing. A. Nanopores in a gold ﬁlm through which there is enhanced transmission of light
plasmon resonance microscopy with intact living cells. (i) Schematic illustration of the
ld image of a cell. (Picture A was modiﬁed fromMaynard et al. [78] and B was modiﬁed
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binding kinetics from thousands of sample spots, thus providing a sig-
niﬁcant enhancement in sensitivity over conventional SPR.
The important drug discovery method of fragment-based screening
has successfully been combined with SPR for the medium-throughput
screening of chemical libraries [81–87]. So far this has mostly been
demonstrated with soluble non-membrane protein targets, but there
is clearly high potential for combining fragment-based drug screening
with the SPR technological advances already described and membrane
protein targets, recently exempliﬁed by results demonstrated with the
β1-adrenergic receptor (Section 4.1.7).
6. Conclusions
This review has demonstrated that SPR is a rapidly developing tech-
nique for the quantitative characterisation of real-time binding and ki-
netics of membrane protein–ligand interactions that is label-free and
uses relatively small quantities of materials. It can be used with a
wide range of membrane protein systems including GPCRs, which are
themajor molecular targets for current validated drugs and for foresee-
able drug discovery. Recent developments in SPR instrumentation,
sensor chip design, sample preparation strategies and the increasing
availability of cloned, stabilised and puriﬁed eukaryotic membrane
proteins shows high potential for medium-throughput screening of li-
braries in the search for new small-molecule and monoclonal antibody
drugs.
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